The US Food and Drug Administration on Tuesday amended the fact sheet for US pharmaceutical company Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine to include a rare risk of immune thrombocytopenia, a bleeding disorder, Reuters news agency reported on Wednesday.
In a letter to Janssen Biotech Inc, J&J's division that manufactures the vaccine, the health regulators said: "Reports of adverse events following use of the Janssen COVID-19 vaccine under emergency use authorisation suggest an increased risk of immune thrombocytopenia during the 42 days following vaccination."
These symptoms include easy bruising or tiny blood spots under the skin, or unusual or excessive bleeding, the FDA said.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT